Home
ASND
ASND News

Latest Ascendis Pharma A/S (ASND) News on July 27, 2024

Despite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 year

Simply Wall St.

2 days ago

Despite shrinking by US$346m in the past week, Ascendis Pharma (NASDAQ:ASND) shareholders are still up 54% over 1 year

2 Biotech Stocks With Big FDA Decisions Approaching – Here’s What Analysts Expect

TipRanks

19 days ago

2 Biotech Stocks With Big FDA Decisions Approaching – Here’s What Analysts Expect

MT Newswires

21 days ago

Ascendis Pharma, Pendopharm Sign Distribution Agreement for TransCon Parathyroid Hormone in Canada

Pendopharm and Ascendis to distribute hypoparathyroidism treatment

Pharmaceutical Technology

22 days ago

Pendopharm and Ascendis to distribute hypoparathyroidism treatment

Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada

CNW Group

22 days ago

Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada

MT Newswires

a month ago

TD Cowen Upgrades Ascendis Pharma to Buy Rating With $175 Price Target

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

GlobeNewswire

a month ago

Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand

Insider Monkey

a month ago

Ascendis Pharma A/S (ASND) Stock Soared on Unexpected Demand

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

2 months ago

Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

MT Newswires

2 months ago

Ascendis Pharma Reports 45% Clinical Response in TransCon IL-2 Phase 1/2 Trial

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

GlobeNewswire

2 months ago

Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024

MT Newswires

2 months ago

Stifel Initiates Ascendis Pharma at Buy Rating With $200 Price Target

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

GlobeNewswire

2 months ago

Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024

FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months

Benzinga

2 months ago

FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

Zacks

2 months ago

FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing

MT Newswires

2 months ago

US Equity Markets Close Higher Tuesday as Producer Prices Rise

MT Newswires

2 months ago

Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop

Reuters

2 months ago

UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy

Reuters

2 months ago

FDA extends review of Ascendis Pharma's hormone disorder therapy

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism

GlobeNewswire

2 months ago

Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with Hypoparathyroidism

MT Newswires

2 months ago

Ascendis Says Late-Stage Trial Shows 'Significant' Improvements in Kidney Function for Adults Treated With TransCon PTH

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

GlobeNewswire

2 months ago

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024

GlobeNewswire

3 months ago

Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024

Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript

Insider Monkey

3 months ago

Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript

Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

3 months ago

Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

MT Newswires

3 months ago

Ascendis Pharma Q1 Net Loss Widens, Revenue Rises

Ascendis Pharma Reports First Quarter 2024 Financial Results

GlobeNewswire

3 months ago

Ascendis Pharma Reports First Quarter 2024 Financial Results

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

GlobeNewswire

3 months ago

Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024

MT Newswires

3 months ago

Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

Zacks

3 months ago

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

GlobeNewswire

3 months ago

United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism

Biotech With 520% Sales Growth Nears Next Buy Point

Investor's Business Daily

4 months ago

Biotech With 520% Sales Growth Nears Next Buy Point

Two Health Care Stocks Outperform S&P 500, Offer Entries

Investor's Business Daily

4 months ago

Two Health Care Stocks Outperform S&P 500, Offer Entries

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Zacks

4 months ago

Are Medical Stocks Lagging AdaptHealth (AHCO) This Year?

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Zacks

4 months ago

Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last?

Ascendis Pharma A/S (ASND) Rose on Positive Trial Results

Insider Monkey

4 months ago

Ascendis Pharma A/S (ASND) Rose on Positive Trial Results

30 Biggest Biotechnology Companies in the World

Insider Monkey

4 months ago

30 Biggest Biotechnology Companies in the World

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

Zacks

5 months ago

The Zacks Analyst Blog Highlights Legend Biotech, Exact Sciences, Exelixis, Ascendis Pharma and MorphoSys

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

Zacks

5 months ago

5 Biotechnology Stocks to Buy for a Stable Portfolio in 2024

Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4

Insider Monkey

5 months ago

Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?

Zacks

5 months ago

Is AdaptHealth (AHCO) Stock Outpacing Its Medical Peers This Year?

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

GlobeNewswire

5 months ago

Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024

Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?

Zacks

5 months ago

Ascendis Pharma A/S (ASND) is a Great Momentum Stock: Should You Buy?

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

Zacks

5 months ago

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

US$172 - That's What Analysts Think Ascendis Pharma A/S (NASDAQ:ASND) Is Worth After These Results

Simply Wall St.

6 months ago

US$172 - That's What Analysts Think Ascendis Pharma A/S (NASDAQ:ASND) Is Worth After These Results

Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript

Insider Monkey

6 months ago

Ascendis Pharma A/S (NASDAQ:ASND) Q4 2023 Earnings Call Transcript

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

GlobeNewswire

6 months ago

Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire

6 months ago

Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

Zacks

6 months ago

Why Earnings Season Could Be Great for Ascendis Pharma (ASND)

Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024

GlobeNewswire

6 months ago

Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

GlobeNewswire

6 months ago

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

Thomson Reuters StreetEvents

6 months ago

Q1 2024 Woodward Inc Earnings Call

Woodward (WWD) Q1 Earnings & Revenues Top Estimates, Rise Y/Y

Zacks

6 months ago

Woodward (WWD) Q1 Earnings & Revenues Top Estimates, Rise Y/Y

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

GlobeNewswire

6 months ago

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

GlobeNewswire

6 months ago

New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

Morningstar Research

6 months ago

Analyst Report: Albemarle Corporation

Dover Corporation (DOV) Earnings Expected to Grow: Should You Buy?

Zacks

6 months ago

Dover Corporation (DOV) Earnings Expected to Grow: Should You Buy?

Top 5 Stocks Poised to Beat on Earnings This Month

Zacks

6 months ago

Top 5 Stocks Poised to Beat on Earnings This Month

Realtor.com® December Rental Report: Price Peak Behind Us as Rents Continue to Fall at Year's End

PR Newswire

6 months ago

Realtor.com® December Rental Report: Price Peak Behind Us as Rents Continue to Fall at Year's End

3 Reasons Roku Stock Could Crush the Market for the Next Decade

Motley Fool

6 months ago

3 Reasons Roku Stock Could Crush the Market for the Next Decade

1 Growth Stock Down 74% to Buy Right Now

Motley Fool

6 months ago

1 Growth Stock Down 74% to Buy Right Now

Why Fortune Brands Innovations (FBIN) is Poised to Beat Earnings Estimates Again

Zacks

6 months ago

Why Fortune Brands Innovations (FBIN) is Poised to Beat Earnings Estimates Again

Albemarle Corporation (NYSE:ALB) is favoured by institutional owners who hold 87% of the company

Simply Wall St.

6 months ago

Albemarle Corporation (NYSE:ALB) is favoured by institutional owners who hold 87% of the company

Strong Second Half Drives 2023 Secondary Deals to $112 Billion

The Wall Street Journal

6 months ago

Strong Second Half Drives 2023 Secondary Deals to $112 Billion

News Corp to Report Fiscal 2024 Second Quarter Earnings

Business Wire

6 months ago

News Corp to Report Fiscal 2024 Second Quarter Earnings

Is It Really Time to Give Up on Roku Stock?

Motley Fool

6 months ago

Is It Really Time to Give Up on Roku Stock?

Is a Beat in Store for D.R. Horton (DHI) in Q1 Earnings?

Zacks

6 months ago

Is a Beat in Store for D.R. Horton (DHI) in Q1 Earnings?

Got $1,000? 3 Top Growth Stocks to Buy That Could Double Your Money.

Motley Fool

6 months ago

Got $1,000? 3 Top Growth Stocks to Buy That Could Double Your Money.

Top 20 Most Valuable Data Companies in the World

Insider Monkey

6 months ago

Top 20 Most Valuable Data Companies in the World

The 3 Most Undervalued Renewable Energy Stocks to Buy in January

InvestorPlace

6 months ago

The 3 Most Undervalued Renewable Energy Stocks to Buy in January

McKesson (MCK) Set to Sell Canadian Rexall Pharmacy Group

Zacks

6 months ago

McKesson (MCK) Set to Sell Canadian Rexall Pharmacy Group

Is Universal Health Services (UHS) a Great Value Stock Right Now?

Zacks

6 months ago

Is Universal Health Services (UHS) a Great Value Stock Right Now?

Northern Trust Corporation (NASDAQ:NTRS) Q4 2023 Earnings Call Transcript

Insider Monkey

6 months ago

Northern Trust Corporation (NASDAQ:NTRS) Q4 2023 Earnings Call Transcript

Should You Be Impressed By Vistra Corp.'s (NYSE:VST) ROE?

Simply Wall St.

6 months ago

Should You Be Impressed By Vistra Corp.'s (NYSE:VST) ROE?

Northern Trust Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

6 months ago

Northern Trust Full Year 2023 Earnings: Misses Expectations

ShockWave Medical Inc President & CEO Douglas Godshall Sells 10,000 Shares

GuruFocus.com

6 months ago

ShockWave Medical Inc President & CEO Douglas Godshall Sells 10,000 Shares

UnionBank Selects Informatica’s AI-Powered Intelligent MDM Solution to Elevate Customer Experience in the Cloud

Business Wire

6 months ago

UnionBank Selects Informatica’s AI-Powered Intelligent MDM Solution to Elevate Customer Experience in the Cloud

Trex Named "America’s Most Trusted® Outdoor Decking" for Fourth Consecutive Year

Business Wire

6 months ago

Trex Named "America’s Most Trusted® Outdoor Decking" for Fourth Consecutive Year

NJ-based Authentication Solutions Provider BIO-key to Review Growth Strategy and Progress at The Microcap Conf. in Atlantic City – Presentation Wed., Jan 31 at 10:50am ET

GlobeNewswire

6 months ago

NJ-based Authentication Solutions Provider BIO-key to Review Growth Strategy and Progress at The Microcap Conf. in Atlantic City – Presentation Wed., Jan 31 at 10:50am ET

BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2024, TO ANNOUNCE SECOND QUARTER FISCAL 2024 FINANCIAL RESULTS

PR Newswire

6 months ago

BIO-TECHNE TO HOST CONFERENCE CALL ON FEBRUARY 1, 2024, TO ANNOUNCE SECOND QUARTER FISCAL 2024 FINANCIAL RESULTS

Business Wire

6 months ago

Jefferies and SMBC Expand and Strengthen Strategic Alliance, Broadening Joint Business Efforts Across EMEA

12 Best Pipeline and MLP Stocks To Buy

Insider Monkey

6 months ago

12 Best Pipeline and MLP Stocks To Buy

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Zacks

6 months ago

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

Why Idex (IEX) is Poised to Beat Earnings Estimates Again

Zacks

6 months ago

Why Idex (IEX) is Poised to Beat Earnings Estimates Again

RenaissanceRe (RNR) is a Top-Ranked Growth Stock: Should You Buy?

Zacks

6 months ago

RenaissanceRe (RNR) is a Top-Ranked Growth Stock: Should You Buy?

14 High Growth NASDAQ Stocks That Are Profitable

Insider Monkey

6 months ago

14 High Growth NASDAQ Stocks That Are Profitable

Is Bio-Techne Corporation's (NASDAQ:TECH) Stock's Recent Performance A Reflection Of Its Financial Health?

Simply Wall St.

6 months ago

Is Bio-Techne Corporation's (NASDAQ:TECH) Stock's Recent Performance A Reflection Of Its Financial Health?

Russian War, Energy Transition Boost Value of Chesapeake Deal

Barrons.com

6 months ago

Russian War, Energy Transition Boost Value of Chesapeake Deal

Oil prices tick up after Iran seizes Iraqi oil vessel

Yahoo Finance Video

6 months ago

Oil prices tick up after Iran seizes Iraqi oil vessel

RenaissanceRe Schedules Fourth Quarter and Year-End 2023 Financial Results Conference Call

Business Wire

6 months ago

RenaissanceRe Schedules Fourth Quarter and Year-End 2023 Financial Results Conference Call

Estimating The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)

Simply Wall St.

7 months ago

Estimating The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)

Jefferies Financial Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Simply Wall St.

7 months ago

Jefferies Financial Group Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Investors ignore increasing losses at Ascendis Pharma (NASDAQ:ASND) as stock jumps 11% this past week

Simply Wall St.

7 months ago

Investors ignore increasing losses at Ascendis Pharma (NASDAQ:ASND) as stock jumps 11% this past week

Jefferies (JEF) Stock Dips 2.3% Despite Q4 Earnings Beat

Zacks

7 months ago

Jefferies (JEF) Stock Dips 2.3% Despite Q4 Earnings Beat

Jefferies Financial Group Inc Reports Modest Returns Amid Economic Transition

GuruFocus.com

7 months ago

Jefferies Financial Group Inc Reports Modest Returns Amid Economic Transition

Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries

GlobeNewswire

7 months ago

Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries

Here's Why You Should Add NiSource (NI) to Your Portfolio Now

Zacks

7 months ago

Here's Why You Should Add NiSource (NI) to Your Portfolio Now

Ascendis Pharma Introduces Vision 2030

GlobeNewswire

7 months ago

Ascendis Pharma Introduces Vision 2030

Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries

PR Newswire

7 months ago

Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries

5 Great REITs To Buy In 2024

Benzinga

7 months ago

5 Great REITs To Buy In 2024

Share on Social Networks: